Search

Janak K Padia

from Tucson, AZ
Age ~64
Get Report
Also known as:
Janak Pallav Padia, Janak Pallavi Padia, Janak Pallari Padia, Janak A Padia, Janak K Pedia, Jamak Padia
Phone and address:
5069 Mesa Crest Pl, Tucson, AZ 85718
(520) 615-4897
Related to:
Manhar C Patel, 79Sanjay J Jajal, 57Pallavi J Padia, 62Umesh J PadiaBharti J Jajal, 68Hiral J Padia, 34Vineet J Padia, 30Jagjiwan G Jajal, 99
Connected to:
Carol A Padia, 63Grant J Padia, 33Lopa D Padia, 39Marci L Padia, 73Victor A Padial, 42Anne B Padias, 75Valerie Padich, 57Arash M Padidar, 61Lauro P Padierna, 30Pedro Padierna, 75

Janak Padia Phones & Addresses

  • 5069 Mesa Crest Pl, Tucson, AZ 85718 (520) 615-4897
  • 5751 Kolb Rd, Tucson, AZ 85750 (520) 615-4897
  • 19 Firstfield Rd, Gaithersburg, MD 20878
  • 13628 Monarch Vista Dr, Germantown, MD 20874 (734) 662-2405
  • Eupora, MS
  • Damascus, MD
  • Ann Arbor, MI
  • Ypsilanti, MI
  • 13628 Monarch Vista Dr, Germantown, MD 20874 (301) 528-9045

Work

Position: Professional/Technical

Education

Degree: Graduate or professional degree

Industries

Research

Resumes

Resumes

Janak Padia Photo 1

Janak Padia

View page
Location:
Washington D.C. Metro Area
Industry:
Research

Publications

Us Patents

Urea Derivatives As Inhibitors For Ccr-3 Receptor

View page
US Patent:
6875884, Apr 5, 2005
Filed:
Jul 28, 2000
Appl. No.:
10/019652
Inventors:
Janak Padia - Tucson AZ, US
Michael Hocker - Tucson AZ, US
Tsuyoshi Nishitoba - Gunma-ken, JP
Hirohi Ohashi - Gunma-ken, JP
Eiji Sawa - Gunma-ken, JP
Assignee:
Kirin Beer Kabushiki Kaisha - Tokyo
International Classification:
C07C205/00
C07C229/00
C07C327/00
C07D215/38
C07D233/61
US Classification:
560 21, 560 34, 560169, 562435, 562 27, 562 28, 562 50, 562 52, 562 56, 546175, 546334, 548253, 5483355, 548504, 548566, 549434, 549 77, 549484
Abstract:
Urea and thiourea derivatives inhibit cell function of the chemokine receptor CCR-3. These compounds offer an effective means for treating a range of diseases thought to be mediated by the CCR-3 receptor. A variety of useful urea and thiourea derivatives can be synthesized using liquid and solid phase synthesis protocols.

Derivatives Of Fluorene, Anthracene, Xanthene, Dibenzosuberone And Acridine And Uses Thereof

View page
US Patent:
8129519, Mar 6, 2012
Filed:
May 9, 2008
Appl. No.:
12/451313
Inventors:
Wieslaw M. Cholody - Frederick MD, US
Yi Zang - Princeton Junction NJ, US
Karina Zuck - Derwood MD, US
Jeffrey W. H. Watthey - Frederick MD, US
Zoe Ohler - Ijamsville MD, US
Jeffrey Strovel - Laurel MD, US
Norman E. Ohler - Ijamsville MD, US
Sheela Chellappan - Germantown MD, US
Janak Padia - Germantown MD, US
International Classification:
C07D 345/00
US Classification:
540 1
Abstract:
Chemical agents, such as disulfonamide derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of the Wnt/β-catenin signaling pathway, and serve to reduce β-catenin levels present in cells, such as cancer cells, or where the agents modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.

Diamine Derivatives Of Quinone And Uses Thereof

View page
US Patent:
20050032794, Feb 10, 2005
Filed:
Jan 15, 2004
Appl. No.:
10/758521
Inventors:
Janak Padia - Germantown MD, US
Sean O'Brien - Gaithersburg MD, US
Jiemin Lu - Germantown MD, US
Stanislaw Pikul - Germantown MD, US
International Classification:
C07D265/36
C07D215/12
A61K031/538
A61K031/517
A61K031/498
A61K031/47
A61K031/165
US Classification:
514230500, 514266100, 514248000, 514249000, 514311000, 514310000, 514619000, 544105000, 544235000, 544283000, 544353000, 546139000, 546176000, 552292000
Abstract:
Diamine derivatives of quinones, and related compounds, including salts thereof, that modulate the levels of gene expression in cellular systems, such as cancer cells, are disclosed, along with methods for preparing such compounds and derivatives, as well as pharmaceutical compositions containing these compounds and derivatives as active ingredients. Methods of using these as compounds and derivatives as therapeutic agents are also described.

Derivatives Of Fluorene, Anthracene, Xanthene, Dibenzosuberone And Acridine And Uses Thereof

View page
US Patent:
20120129837, May 24, 2012
Filed:
Jan 30, 2012
Appl. No.:
13/361761
Inventors:
Wieslaw M. Cholody - Frederick MD, US
Yi Zang - Princeton Junction NJ, US
Norman E. Ohler - Ijamsville MD, US
Sheela Chellappan - Germantown MD, US
Janak Padia - Germantown MD, US
Karina Zuck - Derwood MD, US
Jeffrey W.H. Watthey - Frederick MD, US
Zoe Ohler - Ijamsville MD, US
Jeffrey Strovel - Laurel MD, US
International Classification:
A61K 31/553
A61K 31/473
A61K 31/18
A61K 31/4545
A61K 31/5377
A61K 31/55
A61K 31/551
C07D 403/12
C07D 401/14
C07C 311/37
C07D 401/12
C07D 413/12
A61P 35/00
A61P 35/04
A61K 31/395
US Classification:
51421115, 514183, 514297, 514603, 514316, 5142318, 51421703, 514218, 540480, 546104, 552222, 552210, 546189, 546191, 544 79, 540596, 540575, 540544
Abstract:
Chemical agents, such as disulfonamide derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of the Wnt/β-catenin signaling pathway, and serve to reduce β-catenin levels present in cells, such as cancer cells, or where the agents modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.

Method For Treating And Preventing Inflammation And Atherosclerosis

View page
US Patent:
59729805, Oct 26, 1999
Filed:
Apr 20, 1999
Appl. No.:
9/295742
Inventors:
Joseph Anthony Cornicelli - Ann Arbor MI
Bradley Dean Tait - Canton MI
Bharat Kalidas Trivedi - Farmington Hills MI
Janak Khimchand Padia - Tucson AZ
Assignee:
Warner-Lambert Company - Morris Plains NJ
International Classification:
A61K 31425
A61K 3144
US Classification:
514365
Abstract:
Inhibitors of 15-lipoxygenase (15-LO) are useful to treat and prevent inflammation or atherosclerosis. Preferred inhibitors have a ratio of 5-LO to 15-LO inhibitory activity of at least about 10 or more. Typical 15-LO inhibitors have the formula ##STR1## wherein R. sup. 13 is phenyl, 4-chlorophenyl, 4-fluorophenyl, 4-nitrophenyl, 2,5-dichlorophenyl, 2-furanyl, 2-thienyl, 3-pyridyl, or 4-pyridyl.

Derivatives Of Substituted Morpholines And Uses Thereof

View page
US Patent:
20220306618, Sep 29, 2022
Filed:
Mar 18, 2022
Appl. No.:
17/698592
Inventors:
- Rockville MD, US
Janak Khimchand Padia - Germantown MD, US
Assignee:
Supernus Pharmaceuticals, Inc. - Rockville MD
International Classification:
C07D 413/14
C07D 413/12
C07D 265/30
Abstract:
A compound of Formula I includes a stereoisomer thereof and/or a salt thereof; wherein Ris a substituted alkane group, a heterocylic group, or a pyridine group; X is hydrogen, a halogen, an amino acid residue, a substituted amino acid residue, an alkyl group, or an ester. Such compounds may be used in pharmaceutical compositions and for the treatment of central nervous system (CNS) disorders:

Derivatives Of Substituted Morpholines And Uses Thereof

View page
US Patent:
20220298150, Sep 22, 2022
Filed:
May 25, 2022
Appl. No.:
17/824644
Inventors:
- Rockville MD, US
Janak Khimchand Padia - Germantown MD, US
Assignee:
Supernus Pharmaceuticals, Inc. - Rockville MD
International Classification:
C07D 413/12
C07D 265/30
Abstract:
A compound of Formula I includes a stereoisomer thereof and/or a salt thereof; wherein Ris a substituted alkane group, a heterocylic group, or a pyridine group; X is hydrogen, a halogen, an amino acid residue, a substituted amino acid residue, an alkyl group, or an ester. Such compounds may be used in pharmaceutical compositions and for the treatment of central nervous system (CNS) disorders:

Adenine Analogs, Prodrugs, Derivatives, Compositions And Uses Thereof

View page
US Patent:
20230002389, Jan 5, 2023
Filed:
Jun 9, 2022
Appl. No.:
17/836070
Inventors:
Janak Khimchand Padia - Germantown MD, US
International Classification:
C07D 473/34
Abstract:
The present invention relates to adenine analogs, prodrugs thereof, derivatives thereof, compositions thereof, metabolites thereof, salts thereof, prodrugs thereof, and uses in pharmaceutical compositions containing these compounds, and methods of using these compounds for treating a wide variety of medical conditions, diseases or disorders thereof.
Control profile
Janak K Padia from Tucson, AZ, age ~64 Get Report